PRELIMINARY COPY DATED JULY 8, 2024, SUBJECT TO COMPLETION
☑ | | | Preliminary Proxy Statement |
☐ | | | Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
☐ | | | Definitive Proxy Statement |
☐ | | | Definitive Additional Materials |
☐ | | | Soliciting Material Pursuant to § 240.14a-12 |
☑ | | | No fee required |
☐ | | | Fee paid previously with preliminary materials |
☐ | | | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
• | complete, sign and date the written consent card and return it promptly in the envelope provided; |
• | go to www.proxyvote.com to complete an electronic written consent card. You will be asked to provide the control number from your Notice; or |
• | dial toll-free 1-800-690-6903 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the control number from the Notice. |
• | FOR the approval of an amendment to our Articles of Incorporation to effect a reverse stock split of our outstanding Common Stock at a reverse stock split ratio ranging from any whole number between 1-for-300 and 1-for-500, subject to and as determined by the Board (Proposal 1); and |
• | FOR the approval of the SANUWAVE Health, Inc. 2024 Equity Incentive Plan (Proposal 2). |
• | delivering to the Corporate Secretary of the Company a written notice stating that the written consent is revoked; |
• | signing and delivering a written consent card bearing a later date; |
• | completing a new electronic written consent card over the Internet; or |
• | submitting new instructions by telephone. |
• | Proposal 1. Approval of the amendment to our Articles of Incorporation to effect a reverse stock split of our outstanding Common Stock at a reverse stock split ratio ranging from any whole number between 1-for-300 and 1-for-500, subject to and as determined by the Board, requires the affirmative consent of the holders of a majority of the outstanding shares of Common Stock for approval. Abstentions and any broker non-votes will have the same effect as a written consent “against” Proposal 1. |
• | Proposal 2. Approval of the SANUWAVE Health, Inc. 2024 Equity Incentive Plan requires the affirmative consent of the holders of a majority of the outstanding shares of Common Stock for approval. Abstentions and broker non-votes will have the same effect as a written consent “against” Proposal 2. |
• | the financial consequences to the Company of triggering an event of default under the Notes; |
• | the initial listing requirements for uplisting onto The Nasdaq Capital Market; |
• | the historical trading price and trading volume of our Common Stock; |
• | the then-prevailing trading price and trading volume of our Common Stock and the expected impact of the Reverse Stock Split on the trading market for our Common Stock in the short- and long-term; |
• | the number of shares of our Common Stock outstanding; |
• | the anticipated impact of a particular ratio on the Company’s ability to reduce administrative and transactional costs; and |
• | prevailing general market, legal and economic conditions. |
• | purchasing a sufficient number of shares of our Common Stock; or |
• | if you have shares of our Common Stock in more than one account, consolidating your accounts; |
• | each 300 to 500 shares of our Common Stock owned by a stockholder (depending on the Reverse Stock Split ratio selected by the Board), would be combined into one new share of our Common Stock; |
• | no fractional shares of Common Stock would be issued in connection with the Reverse Stock Split; instead, any stockholders who would have been entitled to receive fractional shares as a result of the Reverse Stock Split will instead receive cash payments in lieu of such fractional shares; |
• | by reducing the number of shares of Common Stock outstanding without reducing the number of shares of available but unissued Common Stock, the Reverse Stock Split will effectively increase the relative number of authorized but unissued shares, which the Board may use in connection with future financings or other issuances; |
• | based upon the Reverse Stock Split ratio selected by the Board of Directors, proportionate adjustments would be made to the per share exercise or conversion price and the number of shares issuable upon the exercise, conversion or vesting of all then outstanding equity awards, Common Stock warrants and convertible debt with respect to the number of shares of Common Stock subject to such award, warrant or convertible debt and the exercise or conversion price thereof, in each case to the extent applicable, subject to the terms of such awards, warrants or convertible debt; |
• | the number of shares of Common Stock authorized under the Amended and Restated 2006 Stock Incentive Plan of SANUWAVE Health, Inc. (the “Prior Plan”) and, if approved, the 2024 Equity Incentive Plan (the “Plan”), will be proportionately adjusted for the Reverse Stock Split ratio selected by the Board; and |
• | the number of stockholders owning “odd lots” of less than 100 shares of our Common Stock may potentially increase; odd lot shares may be more difficult to sell and brokerage commissions and other costs of transactions in odd lots generally are proportionately higher than the costs of transactions in “round lots” of even multiples of 100 shares. |
Status | | | Number of Shares of Common Stock Authorized | | | Number of Shares of Common Stock Issued and Outstanding | | | Number of Shares of Common Stock Underlying Outstanding Options, Warrants and Convertible Notes | | | Number of Shares of Common Stock Authorized but Not Outstanding or Reserved |
Pre-Reverse Stock Split | | | 2,500,000,000 | | | 1,181,272,961 | | | 1,743,910,430 | | | 0 |
Post-Reverse Stock Split 1:300 | | | 2,500,000,000 | | | 3,937,576 | | | 5,813,035 | | | 2,490,249,389 |
Post-Reverse Stock Split 1:320 | | | 2,500,000,000 | | | 3,691,478 | | | 5,449,721 | | | 2,490,858,801 |
Post-Reverse Stock Split 1:340 | | | 2,500,000,000 | | | 3,474,332 | | | 5,129,149 | | | 2,491,396,519 |
Post-Reverse Stock Split 1:360 | | | 2,500,000,000 | | | 3,281,313 | | | 4,844,196 | | | 2,491,874,491 |
Post-Reverse Stock Split 1:380 | | | 2,500,000,000 | | | 3,108,613 | | | 4,589,238 | | | 2,492,302,149 |
Post-Reverse Stock Split 1:400 | | | 2,500,000,000 | | | 2,953,182 | | | 4,359,777 | | | 2,492,687,041 |
Post-Reverse Stock Split 1:420 | | | 2,500,000,000 | | | 2,812,554 | | | 4,152,168 | | | 2,493,035,278 |
Post-Reverse Stock Split 1:440 | | | 2,500,000,000 | | | 2,684,711 | | | 3,963,433 | | | 2,493,351,856 |
Post-Reverse Stock Split 1:460 | | | 2,500,000,000 | | | 2,567,984 | | | 3,791,110 | | | 2,493,640,906 |
Post-Reverse Stock Split 1:480 | | | 2,500,000,000 | | | 2,460,985 | | | 3,633,147 | | | 2,493,905,868 |
Post-Reverse Stock Split 1:500 | | | 2,500,000,000 | | | 2,362,545 | | | 3,487,821 | | | 2,494,149,634 |
• | a U.S. Holder will not recognize gain or loss on the Reverse Stock Split, except with respect to any cash received in lieu of a fractional share of our Common Stock; |
• | the aggregate tax basis of the shares of our Common Stock received by a U.S. Holder in the Reverse Stock Split will be equal to the aggregate tax basis of the shares exchanged therefor, excluding any portion of such basis allocable to a fractional share of our Common Stock; |
• | the holding period of the shares of our Common Stock received by a U.S. Holder in the Reverse Stock Split will include the holding period of the shares exchanged therefor; and |
• | such capital gain or loss will be short term if the shares owned immediately prior to the Reverse Stock Split were held for one year or less at the Effective Time of the Reverse Stock Split and long term if held for more than one year. |
• | A “corporate transaction” generally means (i) a sale or other disposition of all or substantially all of the assets of the Company, or (ii) a merger, consolidation, share exchange or similar transaction involving the Company. |
• | A “change in control” generally refers to a corporate transaction (as defined above), the acquisition by a person or group of beneficial ownership of 30% or more of the voting power of the Company’s stock, or stock equaling 50% or more of the Company’s fair market value, a sale of 40% or more of the assets of the Company, or the Company’s “continuing directors” ceasing to constitute a majority of our Board. |
Name | | | Number of Stock Options |
Morgan Frank | | | — |
Toni Rinow | | | — |
Tim Hendricks | | | 5,000,000 |
Kevin A. Richardson, II | | | 25,000,000 |
All current executive officers as a group | | | 31,105,000 |
All non-employee directors as a group | | | 25,000,000 |
All employees, other than executive officers, as a group | | | 300,000 |
• | Morgan Frank, Chief Executive Officer |
• | Toni Rinow, former Chief Financial Officer |
• | Tim Hendricks, Executive Vice President of Sales |
• | Kevin A. Richardson, II, former Chief Strategy Officer and former Chief Executive Officer |
Name and Position | | | Year | | | Salary | | | Bonus(2) | | | All other compensation(1) | | | Total |
Morgan Frank, Chief Executive Officer | | | 2023 | | | 1 | | | — | | | 100,000 | | | 100,001 |
Toni Rinow, former Chief Financial Officer | | | 2023 | | | 335,000 | | | — | | | — | | | 335,000 |
Tim Hendricks, Executive Vice President of Sales | | | 2023 | | | 244,391 | | | 30,000 | | | 49,067 | | | 323,458 |
Kevin Richardson II, former Chief Executive Officer | | | 2023 | | | 350,000 | | | — | | | 60,000 | | | 410,000 |
| | 2022 | | | 430,583 | | | — | | | 175,000 | | | 605,583 |
(1) | Includes board fees, health, dental, life and disability insurance premiums and 401(k) matching contributions. |
(2) | The bonus paid to Mr. Hendricks in 2023 was a signing bonus. |
Name | | | Number of securities underlying unexercised options exercisable | | | Number of securities underlying options unexercisable | | | Equity incentive plan awards number of securities underlying unexercised unearned options | | | Exercise price ($) | | | Expiration Date |
Kevin A. Richardson, Former Chief Executive Officer | | | 452,381 | | | — | | | — | | | $0.11 | | | 10/1/2025 |
| | 297,619 | | | — | | | — | | | $0.06 | | | 10/1/2025 | |
| | 700,000 | | | — | | | — | | | $0.04 | | | 6/16/2026 | |
| | 594,300 | | | — | | | — | | | $0.18 | | | 11/9/2026 | |
| | 900,000 | | | — | | | — | | | $0.11 | | | 6/14/2027 | |
| | 1,100,000 | | | — | | | — | | | $0.21 | | | 9/20/2028 | |
| | 50,000 | | | — | | | — | | | $0.15 | | | 8/26/2029 |
Director | | | Fee Earned or paid in cash (in thousands) |
Morgan Frank | | | $100 |
A. Michael Stolarski | | | $97 |
Jeff Blizzard | | | $90 |
Ian Miller | | | $90 |
James Tyler | | | $90 |
Kevin Richardson | | | $60 |
Plan category | | | Number of securities to be issued upon exercise of outstanding options, warrants, and rights (a) | | | Weighted- average exercise price of outstanding options, warrants and rights (b) | | | Number of securities remaining available for future issuance under equity compensation plans (c) |
Equity compensation plans approved by security holders | | | — | | | — | | | — |
Equity compensation plans not approved by security holders | | | 16,286,650 | | | $0.28 | | | 5,598,216 |
Total | | | 16,286,650 | | | $0.28 | | | 5,598,216 |
Year | | | Summary Compensation Table Total for PEOs(1)(2) | | | Compensation Actually Paid to PEOs(1)(2) | | | Average Summary Compensation Table Total for Other NEOs(1)(2) ($) | | | Average Compensation Actually Paid to Other NEOs(1)(2) ($) | | | Value of Initial Fixed $100 Investment Based On Total Shareholder Return(3) ($) | | | Net Income (Loss) ($ in millions) ($) | ||||||
| Kevin A. Richardson, II (PEO 1) ($) | | | Morgan C. Frank (PEO 2) ($) | | | Kevin A. Richardson, II (PEO 1) ($) | | | Morgan C. Frank (PEO 2) ($) | | |||||||||||||
2023 | | | 410,000 | | | 100,001 | | | 410,000 | | | 100,001 | | | 329,229 | | | 329,229 | | | $0.22 | | | (25,807) |
2022 | | | 605,583 | | | — | | | 605,583 | | | — | | | 349,526 | | | 349,526 | | | $0.39 | | | (10,293) |
(1) | Our PEOs and Other NEOs for each reported fiscal year were: |
Year | | | PEOs | | | Other NEOs |
2023 | | | Kevin A. Richardson, II Morgan C. Frank | | | Toni Rinow Tim Hendricks |
2022 | | | Kevin A. Richardson, II | | | John Schlechtweg Lisa Sundstrom |
(2) | SEC rules require certain adjustments be made to the Summary Compensation Table (“SCT”) totals to determine “compensation actually paid” (“CAP”) as reported in the Pay Versus Performance Table. CAP does not necessarily represent cash and/or equity value transferred to the applicable NEO without restriction, but rather is a value calculated under applicable SEC rules. A reconciliation of the SCT totals to CAP to our PEOs and our Other NEOs (as an average) is shown below: |
| | 2023 | | | 2022 | |||||||||||||
Equity Adjustments | | | PEO 1 ($) | | | PEO 2 ($) | | | Average of Other NEOs ($) | | | PEO 1 ($) | | | PEO 2 ($) | | | Average of Other NEOs ($) |
Total Compensation from SCT | | | 410,000 | | | 100,001 | | | 329,229 | | | 605,583 | | | — | | | 349,526 |
Adjustments for stock and option awards | | | | | | | | | | | | | ||||||
Subtract SCT amounts of stock and option awards | | | — | | | — | | | — | | | — | | | — | | | — |
Add fair value at year-end of awards granted during the covered fiscal year that are outstanding and unvested at year-end | | | — | | | — | | | — | | | — | | | — | | | — |
+/- The difference between fair value of awards from the end of the prior fiscal year to the end of the covered year for awards granted in any prior fiscal year that are outstanding and unvested at year end | | | — | | | — | | | — | | | — | | | — | | | — |
+/- Add the fair value as of the vesting date for awards granted and vesting during such fiscal year | | | — | | | — | | | — | | | — | | | — | | | — |
+/- The difference in fair value at the end of the prior fiscal year to the vesting date for awards granted in any prior fiscal year for which all applicable vesting conditions were satisfied during such year | | | — | | | — | | | — | | | — | | | — | | | — |
Subtract fair value at end of prior year for awards granted in any prior fiscal year that fail to meet the applicable vesting conditions during such year | | | — | | | — | | | — | | | — | | | — | | | — |
Compensation Actually Paid (as calculated) | | | 410,000 | | | 100,001 | | | 329,229 | | | 605,583 | | | — | | | 349,526 |
(3) | Total shareholder return is calculated based on a fixed investment of one hundred dollars measured from the market close on December 31, 2021 (the last trading day of fiscal 2021) through and including the end of each fiscal year reported in the table. |
Name of Beneficial Owner(1) | | | Number of Shares Beneficially Owned | | | Percent of Shares Outstanding(2) |
Morgan Frank(3) | | | 354,186,625 | | | 25.0% |
Toni Rinow | | | — | | | * |
Timothy Hendricks | | | — | | | * |
Kevin A. Richardson, II(4) | | | 37,145,354 | | | 3.1% |
A. Michael Stolarski(5) | | | 142,896,781 | | | 11.3% |
James Tyler | | | 3,543,750 | | | * |
Ian Miller | | | 18,293,564 | | | 1.5% |
Jeff Blizard | | | — | | | * |
All Directors and Current Executives as a group (12 persons)(6) | | | 562,490,342 | | | 36.6% |
Greater than 5% Holders: | | | | | ||
Opaleye LP(7) | | | 115,493,554 | | | 9.8% |
Manchester Management PR, LLC(3) Manchester Management Company, LLC Manchester Explorer, L.P. James E. Besser | | | 369,129,125 | | | 25.9% |
* | Denotes less than 1% beneficial ownership |
(1) | Unless otherwise noted, each beneficial owner has the same address as the Company. |
(2) | Applicable percentage ownership is based on 1,181,272,961 shares of Common Stock outstanding as of July 3, 2024. “Beneficial ownership” includes shares for which an individual, directly or indirectly, has or shares voting or investment power, or both, and includes options, warrants and convertible promissory notes, that are exercisable within 60 days of July 3, 2024. Unless otherwise indicated, all the listed persons have sole voting and investment power over the shares listed opposite their names. Beneficial ownership as reported in the above table has been determined in accordance with Rule 13d-3 of the Exchange Act. |
(3) | Manchester Management PR, LLC (“Manchester”) and Manchester Management Company, LLC (“GP”) may be deemed to be the owner of 366,879,125 shares of Common Stock. Manchester and GP have the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 122,460,646 shares of Common Stock and 244,418,479 shares of Common Stock underlying warrants and convertible promissory notes. |
(4) | This amount includes 4,094,300 shares of Common Stock underlying options, 13,089,000 shares of Common Stock underlying warrants, and 4,876,409 shares of Common Stock owned directly by Prides Capital Fund I, L.P. Prides Capital Partners LLC is the general partner of Prides Capital Fund I, L.P. and Mr. Richardson is the controlling shareholder of Prides Capital Partners LLC; therefore, under certain provisions of the Exchange Act, he may be deemed to be the beneficial owner of such securities. Mr. Richardson has also been deputized by Prides Capital Partners LLC to serve on the board of directors of the Company. Mr. Richardson disclaims beneficial ownership of all such securities except to the extent of any indirect pecuniary interest (within the meaning of Rule 16a-1 of the Exchange Act) therein. |
(5) | This amount includes 1,069,800 shares of Common Stock underlying options and 83,560,218 shares of Common Stock underlying warrants and convertible promissory notes. |
(6) | This amount includes 10,813,100 shares of Common Stock underlying options and 343,567,697 shares of Common Stock underlying warrants and convertible promissory notes. |
(7) | Opaleye Management Inc. (the “Opaleye”) serves as investment manager to Opaleye, L.P. and as a portfolio manager for a separate managed account (the “Managed Account”) and may be deemed to indirectly beneficially own securities owned by the Managed Account. Opaleye disclaims beneficial ownership of the shares held by the Managed Account. Mr. James Silverman is the President of Opaleye. The address of Opaleye is One Boston Place, 26th Floor, Boston, MA 02108. |